▶ 調査レポート

世界の線維筋痛症抗うつ薬市場

• 英文タイトル:Market Study on Fibromyalgia Antidepressants: Duloxetine HCl Holds High Share and Drives Market Revenue

Market Study on Fibromyalgia Antidepressants: Duloxetine HCl Holds High Share and Drives Market Revenue「世界の線維筋痛症抗うつ薬市場」(市場規模、市場予測)調査レポートです。• レポートコード:PMR2201A034
• 出版社/出版日:Persistence Market Research / 2021年10月14日
• レポート形態:英文、PDF、245ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥622,300 (USD4,900)▷ お問い合わせ
  Site Licence¥965,200 (USD7,600)▷ お問い合わせ
  Enterprisewide¥1,346,200 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Persistence Market Research社の本調査レポートは、世界の線維筋痛症抗うつ薬市場について調査し、エグゼクティブサマリー、市場概要、主要市場動向、市場背景、新型コロナウイルス感染症の危機影響分析、市場需要分析/予測、医薬品クラス別(ベンラファキシン、デュロキセチン、ミルナシプランHCL、その他)分析、流通チャンネル別(病院薬局、小売薬局、ドラッグストア、オンライン販売)分析、地域別分析、主要国分析、主要構造分析、競争分析、仮定、調査手法などを掲載しています。
・エグゼクティブサマリー
・市場概要
・主要市場動向
・市場背景
・新型コロナウイルス感染症の危機影響分析
・市場需要分析/予測
・世界の線維筋痛症抗うつ薬市場規模:医薬品クラス別(ベンラファキシン、デュロキセチン、ミルナシプランHCL、その他)
・世界の線維筋痛症抗うつ薬市場規模:流通チャンネル別(病院薬局、小売薬局、ドラッグストア、オンライン販売)
・世界の線維筋痛症抗うつ薬市場規模:地域別
・主要国分析
・主要構造分析
・競争分析
・仮定
・調査手法

Fibromyalgia Antidepressants Market- Scope of Report

The latest publication by Persistence Market Research on the fibromyalgia antidepressants market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2021-2031.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for fibromyalgia antidepressants and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the fibromyalgia antidepressants market. The insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the fibromyalgia antidepressants market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the market are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments
Persistence Market Research’s study on the fibromyalgia antidepressants market offers information divided into three important segments – drug class, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug Class
Venlafaxine
Duloxetine HCl
Milnacipran HCl
Others

Distribution Channel
Hospitals Pharmacies
Drug Stores
Retail Pharmacies
Online Sales

Region
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)

Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for fibromyalgia antidepressants over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the market avail themselves the growth opportunities in developed and emerging sectors?

Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the fibromyalgia antidepressants market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market, and makes Persistence Market Research’s projections on the growth prospects of the fibromyalgia antidepressants market more accurate and reliable.

レポート目次

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Technology Roadmap

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Development Trends

3.2. Pipeline Assessment

3.3. Key Regulations

4. Market Background

4.1. Macro-Economic Factors

4.1.1. Global GDP Growth Outlook

4.1.2. Global Healthcare Expenditure

4.1.3. Increase in Pharmaceutical Expenditure

4.2. Forecast Factors – Relevance & Impact

4.2.1. Key Players Historical Growth

4.2.2. Growing Burden of Fibromyalgia Patients

4.2.3. Funding’s/Grant’s for fibromyalgia research

4.2.4. Development of Novel Therapies

4.2.5. Robust Clinical Pipeline

4.2.6. New Drug Approvals

4.2.7. Cost of Fibromyalgia Treatment

4.2.8. Growing Musculoskeletal Disorders

4.2.9. Key Strategic Developments

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunity Analysis

5. COVID19 Crisis Impact Analysis

5.1. Current COVID-19 Statistics and Probable Future Impact

5.2. COVID19 and Impact Analysis overview

5.3. COVID 19 and Impact analysis on Fibromyalgia Antidepressants Market

5.4. COVID 19 and Impact analysis

5.4.1. Revenue Revenue By Drug Class

5.4.2. Revenue By Distribution channel

5.4.3. Revenue By Region

5.5. COVID 19 and Impact analysis Summary

6. Global Fibromyalgia Antidepressants Market Value (US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031

6.1. Historical Market Value (US$ Mn) Analysis, 2016-2020

6.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031

6.2.1. Y-o-Y Growth Trend Analysis

6.2.2. Absolute $ Opportunity Analysis

7. Global Fibromyalgia Antidepressants Market and Volume Analysis 2016-2020 and Forecast, 2021-2031, By Drug Class

7.1. Introduction / Key Findings

7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug Class, 2016-2020

7.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast By Drug Class, 2021 – 2031

7.3.1. Venlafaxine

7.3.2. Duloxetine

7.3.3. Milnacipran HCL

7.3.4. Others

7.4. Market Attractiveness Analysis By Drug Class

8. Global Fibromyalgia Antidepressants Market Analysis 2016-2020 and Forecast, 2021-2031, By Distribution Channel

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016-2020

8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021-2031

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Drug Stores

8.3.4. Online Sales

8.4. Market Attractiveness Analysis By Distribution Channel

9. Global Fibromyalgia Antidepressants Market Analysis 2016-2020 and Forecast, 2021-2031, By Region

9.1. Introduction

9.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2020

9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031

9.3.1. North America

9.3.2. Latin America

9.3.3. Europe

9.3.4. East Asia

9.3.5. South Asia

9.3.6. Oceania

9.3.7. Middle East and Africa (MEA)

9.4. Market Attractiveness Analysis By Region

10. North America Fibromyalgia Antidepressants Market Analysis 2016-2020 and Forecast, 2021-2031

10.1. Introduction

10.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2016-2020

10.3. Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2021-2031

10.3.1. By Country

10.3.1.1. U.S.

10.3.1.2. Canada

10.3.2. By Drug Class

10.3.3. By Distribution Channel

10.4. Market Attractiveness Analysis

10.5. Key Market Participants – Intensity Mapping

10.6. Drivers and Restraints – Impact Analysis

11. Latin America Fibromyalgia Antidepressants Market Analysis 2016-2020 and Forecast, 2021-2031

11.1. Introduction

11.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2016-2020

11.3. Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2021-2031

11.3.1. By Country

11.3.1.1. Brazil

11.3.1.2. Mexico

11.3.1.3. Argentina

11.3.1.4. Rest of Latin America

11.3.2. By Drug Class

11.3.3. By Distribution Channel

11.4. Market Attractiveness Analysis

11.5. Key Market Participants – Intensity Mapping

11.6. Drivers and Restraints – Impact Analysis

12. Europe Fibromyalgia Antidepressants Market Analysis 2016-2020 and Forecast, 2021-2031

12.1. Introduction

12.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2016-2020

12.3. Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2021-2031

12.3.1. By Country

12.3.1.1. Germany

12.3.1.2. Italy

12.3.1.3. France

12.3.1.4. U.K.

12.3.1.5. Spain

12.3.1.6. BENELUX

12.3.1.7. Russia

12.3.1.8. Rest of Europe

12.3.2. By Drug Class

12.3.3. By Distribution Channel

12.4. Market Attractiveness Analysis

12.5. Key Market Participants – Intensity Mapping

12.6. Drivers and Restraints – Impact Analysis

13. South Asia Fibromyalgia Antidepressants Market Analysis 2016-2020 and Forecast, 2021-2031

13.1. Introduction

13.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2016-2020

13.3. Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2021-2031

13.3.1. By Country

13.3.1.1. India

13.3.1.2. Thailand

13.3.1.3. Indonesia

13.3.1.4. Malaysia

13.3.1.5. Rest of South Asia

13.3.2. By Drug Class

13.3.3. By Distribution Channel

13.4. Market Attractiveness Analysis

13.5. Key Market Participants – Intensity Mapping

13.6. Drivers and Restraints – Impact Analysis

14. East Asia Fibromyalgia Antidepressants Market Analysis 2016-2020 and Forecast, 2021-2031

14.1. Introduction

14.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2016-2020

14.3. Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2021-2031

14.3.1. By Country

14.3.1.1. China

14.3.1.2. Japan

14.3.1.3. South Korea

14.3.2. By Drug Class

14.3.3. By Distribution Channel

14.4. Market Attractiveness Analysis

14.5. Key Market Participants – Intensity Mapping

14.6. Drivers and Restraints – Impact Analysis

15. Oceania Fibromyalgia Antidepressants Market Analysis 2016-2020 and Forecast, 2021-2031

15.1. Introduction

15.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2016-2020

15.3. Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2021-2031

15.3.1. By Country

15.3.1.1. Australia

15.3.1.2. New Zealand

15.3.2. By Drug Class

15.3.3. By Distribution Channel

15.4. Market Attractiveness Analysis

15.5. Key Market Participants – Intensity Mapping

15.6. Drivers and Restraints – Impact Analysis

16. Middle East and Africa Fibromyalgia Antidepressants Market Analysis 2016-2020 and Forecast, 2021-2031

16.1. Introduction

16.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis By Market Taxonomy, 2016-2020

16.3. Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2021-2031

16.3.1. By Country

16.3.1.1. GCC Countries

16.3.1.2. South Africa

16.3.1.3. Rest of Middle East and Africa

16.3.2. By Drug Class

16.3.3. By Distribution Channel

16.4. Market Attractiveness Analysis

16.5. Key Market Participants-Intensity Mapping

16.6. Drivers and Restraints-Impact Analysis

17. Key and Emerging Countries Fibromyalgia Antidepressants Market Analysis 2016-2020 and Forecast, 2021-2031

17.1. Introduction

17.1.1. Market Value Proportion Analysis, By Key Countries

17.1.2. Global Vs. Country Growth Comparison

17.2. U.S. Fibromyalgia Antidepressants Market Analysis

17.2.1. By Drug Class

17.2.2. By Distribution Channel

17.3. Canada Fibromyalgia Antidepressants Market Analysis

17.3.1. By Drug Class

17.3.2. By Distribution Channel

17.4. Mexico Fibromyalgia Antidepressants Market Analysis

17.4.1. By Drug Class

17.4.2. By Distribution Channel

17.5. Brazil Fibromyalgia Antidepressants Market Analysis

17.5.1. By Drug Class

17.5.2. By Distribution Channel

17.6. U.K. Fibromyalgia Antidepressants Market Analysis

17.6.1. By Drug Class

17.6.2. By Distribution Channel

17.7. Germany Fibromyalgia Antidepressants Market Analysis

17.7.1. By Drug Class

17.7.2. By Distribution Channel

17.8. France Fibromyalgia Antidepressants Market Analysis

17.8.1. By Drug Class

17.8.2. By Distribution Channel

17.9. Italy Fibromyalgia Antidepressants Market Analysis

17.9.1. By Drug Class

17.9.2. By Distribution Channel

17.10. Spain Fibromyalgia Antidepressants Market Analysis

17.10.1. By Drug Class

17.10.2. By Distribution Channel

17.11. BENELUX Fibromyalgia Antidepressants Market Analysis

17.11.1. By Drug Class

17.11.2. By Distribution Channel

17.12. Russia Fibromyalgia Antidepressants Market Analysis

17.12.1. By Drug Class

17.12.2. By Distribution Channel

17.13. China Fibromyalgia Antidepressants Market Analysis

17.13.1. By Drug Class

17.13.2. By Distribution Channel

17.14. Japan Fibromyalgia Antidepressants Market Analysis

17.14.1. By Drug Class

17.14.2. By Distribution Channel

17.15. South Korea Fibromyalgia Antidepressants Market Analysis

17.15.1. By Drug Class

17.15.2. By Distribution Channel

17.16. India Fibromyalgia Antidepressants Market Analysis

17.16.1. By Drug Class

17.16.2. By Distribution Channel

17.17. ASEAN Fibromyalgia Antidepressants Market Analysis

17.17.1. By Drug Class

17.17.2. By Distribution Channel

17.18. Australia Fibromyalgia Antidepressants Market Analysis

17.18.1. By Drug Class

17.18.2. By Distribution Channel

17.19. New Zealand Fibromyalgia Antidepressants Market Analysis

17.19.1. By Drug Class

17.19.2. By Distribution Channel

17.20. GCC Countries Fibromyalgia Antidepressants Market Analysis

17.20.1. By Drug Class

17.20.2. By Distribution Channel

17.21. Turkey Fibromyalgia Antidepressants Market Analysis

17.21.1. By Drug Class

17.21.2. By Distribution Channel

17.22. South Africa Fibromyalgia Antidepressants Market Analysis

17.22.1. By Drug Class

17.22.2. By Distribution Channel

18. Market Structure Analysis

18.1. Market Analysis by Tier of Companies

18.2. Market Concentration

18.3. Market Share Analysis of Top Players

18.4. Market Presence Analysis

18.4.1. By Regional Footprint of Players

18.4.2. Product Footprint by Players

18.4.3. Channel Footprint by Players

19. Competition Analysis

19.1. Competition Dashboard

19.2. Competition Benchmarking

19.3. Competition Deep Dive

19.3.1. Pfizer, Inc.

19.3.1.1. Product Type Portfolio

19.3.1.2. Profitability by Market Segments (Drug Class/Distribution Channel/Region)

19.3.1.3. Sales Footprint

19.3.1.4. Analyst commentary

19.3.2. Eli Lilly and Company.

19.3.2.1. Product Type Portfolio

19.3.2.2. Profitability by Market Segments (Drug Class/Distribution Channel/Region)

19.3.2.3. Sales Footprint

19.3.2.4. Analyst commentary

19.3.3. AbbVie, Inc

19.3.3.1. Product Type Portfolio

19.3.3.2. Profitability by Market Segments (Drug Class/Distribution Channel/Region)

19.3.3.3. Sales Footprint

19.3.3.4. Analyst commentary

19.3.4. TONIX Pharmaceuticals Holdings Corp

19.3.4.1. Product Type Portfolio

19.3.4.2. Profitability by Market Segments (Drug Class/Distribution Channel/Region)

19.3.4.3. Sales Footprint

19.3.4.4. Analyst commentary

19.3.5. Virios Therapeutics, Inc.

19.3.5.1. Product Type Portfolio

19.3.5.2. Profitability by Market Segments (Drug Class/Distribution Channel/Region)

19.3.5.3. Sales Footprint

19.3.5.4. Analyst commentary

19.3.6. Aptinyx Inc.

19.3.6.1. Product Type Portfolio

19.3.6.2. Profitability by Market Segments (Drug Class/Distribution Channel/Region)

19.3.6.3. Sales Footprint

19.3.6.4. Analyst commentary

20. Assumptions and Acronyms Used

21. Research Methodology

Table 01: Global Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 02: Global Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 03: Global Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Region

Table 04: North America Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 05: North America Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 06: North America Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 07: Latin America Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 08: Latin America Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 09: Latin America Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 10: Europe Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 11: Europe Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 12: Europe Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 13: South Asia Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 14: South Asia Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 15: South Asia Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 16: East Asia Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 17: East Asia Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 18: East Asia Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 19: Oceania Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 20: Oceania Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 21: Oceania Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 22: MEA Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 23: MEA Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 24: MEA Fibromyalgia Antidepressants Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country